National Health Act 1953 - Declaration under subsection 85(2AA) (No. PB 4 of 1995)

Overview

The National Health Act 1953 was enacted to provide a framework for the administration of health services and the regulation of pharmaceutical benefits in Australia. This legislation was introduced to address the need for a comprehensive system to ensure the provision of essential health services and the regulation of pharmaceutical products. The Act is administered by the Commonwealth Parliament and aims to facilitate equitable access to health care and medicines. The Pharmaceutical Benefits Declaration under subsection 85(2AA) of the Act, issued on 15 March 1995 by David Trevor Graham, Assistant Secretary of the Pharmaceutical Benefits Branch within the Department of Human Services and Health, exemplifies the Act's role in regulating the pharmaceutical benefits schedule by removing certain drugs and medicinal preparations from the list of those covered under Part VII of the Act. This specific declaration, effective from 1 April 1995, removed Flumethasone Pivalate with Clioquinol and Fluocortolone Pivalate with Fluocortolone Hexanoate from the Pharmaceutical Benefits Scheme.

Scope and Application

The National Health Act 1953, as amended through the Pharmaceutical Benefits Declaration under Subsection 85 (2AA), applies to the cessation of certain drugs and medicinal preparations from the scope of Part VII of the Act. Specifically, the legislation identifies particular pharmaceutical products, such as Flumethasone Pivalate with Clioquinol and Fluocortolone Pivalate with Fluocortolone Hexanoate, which are to be removed from the list of substances eligible for benefits under the Pharmaceutical Benefits Scheme. This Act operates within the Commonwealth jurisdiction, impacting all entities and individuals across Australia who may have been involved in the provision, supply, or prescription of these specified drugs. The declared changes took effect from 1 April 1995, and the legislation does not specify any exclusions or exemptions beyond the clearly identified substances. Any further refinement or expansion of the application of this Act may be achieved through subordinate instruments, which can be promulgated by the relevant authorities as needed.

Key Provisions

The main operative sections of the Pharmaceutical Benefits Declaration under subsection 85(2AA) of the National Health Act 1953 (section 2) detail the cessation of certain drugs and medicinal preparations from being covered under Part VII of the Act. Specifically, the declaration made by David Trevor Graham, the Assistant Secretary and Delegate of the Minister for Human Services and Health, indicates that as of 1 April 1995, the drugs Flumethasone Pivalate with Clioquinol and Fluocortolone Pivalate with Fluocortolone Hexanoate will no longer be subject to the provisions of Part VII of the Act (section 2). These changes are formalised through the Schedule attached to the declaration, which lists the specific preparations affected by this decision. The obligations and requirements imposed by this Act primarily revolve around the compliance of pharmaceutical entities and healthcare providers. Once the declaration takes effect, any drugs or preparations specified in the Schedule are no longer eligible for the benefits outlined in Part VII of the Act. This includes provisions related to the Pharmaceutical Benefits Scheme (PBS), which subsidises the cost of certain medications for Australian citizens and permanent residents. Therefore, healthcare providers and patients must be aware of the exclusions and adjust their practices and prescriptions accordingly. Pharmaceutical companies must also update their listings and marketing materials to reflect these changes, ensuring they do not claim eligibility for the benefits that are no longer applicable. In terms of the consequences for breaches of the Act, it is important to note that while the primary focus of the Act is on regulatory compliance and updating the list of covered medications, non-compliance could indirectly lead to issues under other sections of the National Health Act or related regulations. For example, if a healthcare provider continues to claim PBS benefits for medications no longer listed, they could potentially face penalties under other health-related legislation. Additionally, pharmaceutical companies that fail to update their product information to reflect these changes could face legal and reputational risks. While the specific penalties for non-compliance are not detailed in this declaration, they could range from fines to more severe legal actions depending on the nature and extent of the breach.